Form 4 for DSS DSS, INC.

Accepted 2022-12-14 00:00:00 ET · period of report 2022-12-13 · accession 0001493152-22-035493 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
	2022-12-14	2022-12-13	DSS	Chan Heng Fai Ambrose	Dir, 10%	P - Purchase	$0.23	+334.9K	18.91M	+2%	+$77.0K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2022-12-13	P	A	334,921	$0.23	18,914,326	D	—	—	(F1) On December 13, 2022, the reporting person purchased 334,921 shares of the Issuer's common stock. This transaction was executed in multiple trades at prices ranging from $0.1899 to $0.25. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide, upon request of the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. (F2) The beneficial ownership of Heng Fai Chan includes a total of 81,786,142 shares of common stock, consisting of (a) 59,552 shares of common stock held by Heng Fai Holdings Limited, an entity controlled by Heng Fai Chan; (b) 18,914,326 shares of common stock held by Heng Fai Chan directly; (c) 35,213,416 shares of common stock held by Alset Inc.; (d) 21,366,177 shares of common stock held by Alset International Limited, a subsidiary of Alset Inc.; and (e) 6,232,671 shares of common stock held by Global Biomedical Pte. Ltd., a subsidiary of Alset International Limited. Mr. Chan, as indirect beneficial owner, has dispositive control over the securities of the Issuer owned by Alset Inc., Alset International Limited and Global Biomedical Pte. Ltd.